As part of an application to the EIC Pathfinder Open 2026 call, EU-based industrial partners are sought to support scale-up, regulatory development, and first-in-human clinical translation of innovative small-molecule modulators and targeted nanomedicine platforms. Dual-action technologies selectively influence mitochondrial and bacterial ion pathways to reprogram tumor immunity and gut microbiota, boosting the efficacy of anti-Programmed death-1 (PD-1) immunotherapy.
Ref.RDRMD20260622006.Un hospital terciario de Moldavia con cepas resistentes a los antimicrobianos busca socios de I+D para el programa Horizonte Europa(HORIZON-HLTH-2027-01-DISEASE-08).
A tertiary hospital in the Republic of Moldova, with about 30 clinical departments, 772 beds and an active clinical microbiology laboratory, seeks R&D partners for Horizon Europe call HORIZON-HLTH-2027-01-DISEASE-08 on innovative antimicrobials. The hospital...
Jun 25, 2026















